CRIS Current Research Information System

FORNARI, FRANCESCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.635
AS - Asia 3.564
EU - Europa 2.511
Continente sconosciuto - Info sul continente non disponibili 255
AF - Africa 184
SA - Sud America 148
OC - Oceania 2
Totale 10.299
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.553
SG - Singapore 920
CN - Cina 890
VN - Vietnam 855
IT - Italia 853
GB - Regno Unito 346
HK - Hong Kong 271
DE - Germania 239
SE - Svezia 209
FR - Francia 159
NL - Olanda 151
IN - India 150
KR - Corea 104
BR - Brasile 103
BD - Bangladesh 89
RU - Federazione Russa 87
FI - Finlandia 84
IE - Irlanda 84
JP - Giappone 75
CH - Svizzera 74
UA - Ucraina 58
ZA - Sudafrica 58
BG - Bulgaria 51
CA - Canada 50
CI - Costa d'Avorio 35
SC - Seychelles 35
ID - Indonesia 32
TH - Thailandia 31
PH - Filippine 28
EE - Estonia 25
TG - Togo 25
JO - Giordania 19
AT - Austria 18
PK - Pakistan 18
PL - Polonia 18
MX - Messico 16
AR - Argentina 15
EU - Europa 15
TW - Taiwan 12
BE - Belgio 11
EC - Ecuador 11
IQ - Iraq 11
TR - Turchia 11
HR - Croazia 10
DZ - Algeria 8
ES - Italia 7
JM - Giamaica 7
UZ - Uzbekistan 6
EG - Egitto 5
GR - Grecia 5
IL - Israele 5
LT - Lituania 5
MY - Malesia 5
PE - Perù 5
CZ - Repubblica Ceca 4
PY - Paraguay 4
SA - Arabia Saudita 4
AE - Emirati Arabi Uniti 3
CL - Cile 3
IR - Iran 3
NG - Nigeria 3
NP - Nepal 3
TN - Tunisia 3
UY - Uruguay 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AZ - Azerbaigian 2
CO - Colombia 2
CR - Costa Rica 2
ET - Etiopia 2
GH - Ghana 2
HN - Honduras 2
HU - Ungheria 2
KG - Kirghizistan 2
KZ - Kazakistan 2
LB - Libano 2
MA - Marocco 2
MD - Moldavia 2
OM - Oman 2
PS - Palestinian Territory 2
RO - Romania 2
SK - Slovacchia (Repubblica Slovacca) 2
SN - Senegal 2
AM - Armenia 1
AU - Australia 1
BO - Bolivia 1
BY - Bielorussia 1
DK - Danimarca 1
GE - Georgia 1
GP - Guadalupe 1
GT - Guatemala 1
KE - Kenya 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LK - Sri Lanka 1
LV - Lettonia 1
LY - Libia 1
ML - Mali 1
MM - Myanmar 1
NC - Nuova Caledonia 1
NI - Nicaragua 1
Totale 10.054
Salva come PNG Salva come JPEG
Città #
Singapore 664
Ashburn 432
Southend 285
Fairfield 257
Bologna 256
San Jose 248
Hong Kong 244
Hefei 205
Ho Chi Minh City 204
Hanoi 195
Chandler 184
Woodbridge 135
Santa Clara 133
Houston 124
Boardman 122
Council Bluffs 121
Seattle 121
Wilmington 111
Beijing 110
Ann Arbor 95
Seoul 92
Dublin 84
Dallas 79
Princeton 78
Los Angeles 77
Helsinki 73
Milan 69
Bern 68
Lauterbourg 68
Cambridge 64
New York 59
Tokyo 57
Sofia 50
Da Nang 47
Abidjan 35
Dong Ket 35
Jacksonville 32
Johannesburg 30
Nanjing 30
Haiphong 29
Padova 29
San Diego 28
Amsterdam 27
Westminster 27
Chicago 26
Redondo Beach 26
Florence 25
Lomé 25
Buffalo 24
São Paulo 23
Munich 22
Frankfurt am Main 21
Jinan 21
Jakarta 20
Amman 19
Bengaluru 18
Berlin 18
Montreal 18
Rome 18
Guangzhou 17
Orem 16
Nanchang 15
Rimini 15
Saint Petersburg 15
Hebei 14
London 14
Phoenix 14
Turin 14
Warsaw 14
Bangkok 13
Brooklyn 12
Imola 12
Modena 12
Parma 12
Shanghai 12
Verona 12
Vienna 12
Zhengzhou 12
Brussels 11
Hải Dương 11
Nuremberg 11
Treviso 11
Changsha 10
Düsseldorf 10
Pune 10
San Giorgio di Piano 10
Shenyang 10
Shenzhen 10
Toronto 10
Atlanta 9
Hangzhou 9
Lahore 9
Mexico City 9
Mülheim 9
Can Tho 8
Chennai 8
Des Moines 8
Falls Church 8
Ferrara 8
Forlì 8
Totale 6.301
Salva come PNG Salva come JPEG
Nome #
Aflatoxin B1 DNA-Adducts in Hepatocellular Carcinoma from a Low Exposure Area 334
Gut Microbiome Modulation in Hepatocellular Carcinoma: Preventive Role in NAFLD/NASH Progression and Potential Applications in Immunotherapy-Based Strategies 292
Circulating microRNAs, MIR-939, MIR-595, MIR-519d and MIR-494, identify cirrhotic patients with HCC 289
In hepatocellular carcinoma miR-221 modulates sorafenib resistance through inhibition of caspase-3–mediated apoptosis 273
Therapeutic dosages of aspirin counteract the IL-6 induced pro-tumorigenic effects by slowing down the ribosome biogenesis rate 252
MiR-494 induces metabolic changes through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma 245
MiR-30e-3p influences tumor phenotype through MDM2/TP53 axis and predicts sorafenib resistance in hepatocellular carcinoma 239
MiR-22/GLUT1 Axis Induces Metabolic Reprogramming and Sorafenib Resistance in Hepatocellular Carcinoma 232
Early CTLA4 increase in CD45+ blood cells: an emerging biomarker of atezolizumab–bevacizumab resistance and worse survival in advanced hepatocarcinoma 228
LncRNAs as novel players in hepatocellular carcinoma recurrence 228
Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. 205
MicroRNA-Based Prophylaxis in a Mouse Model of Cirrhosis and Liver Cancer 201
Circulating CD8 lymphocytes predict response to atezolizumab–bevacizumab in hepatocellular carcinoma 192
MicroRNAs at the Crossroad between Immunoediting and Oncogenic Drivers in Hepatocellular Carcinoma 190
In hepatocellular carcinoma miR-519d is up-regulated by p53 and DNA hypomethylation and targets CDKN1A/p21, PTEN, AKT3 and TIMP2. 190
Noncoding RNAs in Hepatocellular Carcinoma: Potential Applications in Combined Therapeutic Strategies and Promising Candidates of Treatment Response 189
CDKN1C/P57 Is Regulated by the Notch Target Gene Hes1 and Induces Senescence in Human Hepatocellular Carcinoma. 189
The epigenetically regulated miR-494 associates with stem-cell phenotype and induces sorafenib resistance in hepatocellular carcinoma 188
Direct antiviral treatments for hepatitis c virus have off-target effects of oncologic relevance in hepatocellular carcinoma 184
MiR-199-3p replacement affects E-cadherin expression through Notch1 targeting in hepatocellular carcinoma 182
p53/mdm2 feedback loop sustains miR-221 expression and dictates the response to anticancer treatments in hepatocellular carcinoma 178
Hepatic cancer stem cells: Molecular mechanisms, therapeutic implications, and circulating biomarkers 176
MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. 170
MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. 170
TP53/MicroRNA interplay in hepatocellular carcinoma 169
Oncogenic role of miR-483-3p at the IGF2/483 locus. 165
Design, Synthesis and Biological Evaluation of Pyrazole derivatives as Potential multikinase Inhibitors in Hepatocarcinoma. 165
Animal Models of Hepatocellular Carcinoma: Current Applications in Clinical Research 163
F.N.27 NOTCH SIGNALLING CONTROLS PROLIFERATION AND SENESCENCE OF HUMAN HEPATOCELLULAR CARCINOMA 162
MiR-122/Cyclin G1 Interaction Modulates p53 Activity and Affects Doxorubicin Sensitivity of Human Hepatocarcinoma Cells. 160
Liver tumorigenicity promoted by microRNA-221 in a mouse transgenic model 156
Significance of serum and hepatic microRNA-122 levels in patients with non-alcoholic fatty liver disease. 155
Elucidating the Molecular Basis of Sorafenib Resistance in HCC: Current Findings and Future Directions 154
Association of NOS3 and ANGPT2 Gene Polymorphisms with Survival in Patients with Hepatocellular Carcinoma Receiving Sorafenib: Results of the Multicenter Prospective INNOVATE Study 151
MicroRNAs in Animal Models of HCC 150
MicroRNA as predictive biomarkers of treatment response to tyrosine kinase inhibitors in hepatocellular carcinoma: how much is missing? 145
Direct relationship between the level of p53 stabilization induced by rRNA synthesis-inhibiting drugs and the cell ribosome biogenesis rate 143
MiR-221 controls CDKN1C/p57 and CDKN1B/p27 expression in human hepatocellular carcinoma. 142
MicroRNA involvement in hepatocellular carcinoma. 140
Suppression of p53 by Notch3 is mediated by Cyclin G1 and sustained by MDM2 and miR-221 axis in hepatocellular carcinoma. 139
The Natural Inhibitor of DNA Topoisomerase I, Camptothecin, Modulates HIF-1 alpha Activity by Changing miR Expression Patterns in Human Cancer Cells 138
Over-expression of the miR-483-3p overcomes the miR-145/TP53 pro-apoptotic loop in hepatocellular carcinoma 128
MiR-122 targets serpinB3 and is involved in sorafenib resistance in hepatocellular carcinoma 119
Mir-30e-3p/CXCL3 axis is involved in sorafenib resistance of hepatocellular carcinoma through the modulation of the tumor immune microenvironment 118
MicroRNAs as Modulators of Tumor Metabolism, Microenvironment, and Immune Response in Hepatocellular Carcinoma 116
Notch signaling regulation in HCC: From hepatitis virus to non‐coding rnas 115
Low-Baseline PD1+ Granulocytes Predict Responses to Atezolizumab–Bevacizumab in Hepatocellular Carcinoma 115
Thyroid hormone inhibits hepatocellular carcinoma progression via induction of differentiation and metabolic reprogramming 110
Gut microbiome alterations and lenvatinib resistance in hepatocellular carcinoma: the role of Akkermansia muciniphila postbiotics in treatment enhancement 109
null 101
miR-30e-3p/CXCL3 axis predicts early tumor escape in sorafenib-treated hepatocellular carcinoma patients. 94
miR-30e-3p/CXCL3 axis predicts early tumor escape in hepatocellular carcinoma patients undergoing sorafenib treatment 82
MiR-22-3p targets the G2/M checkpoint inhibitor Wee1 and represents a possible biomarker of TACE response in hepatocellular carcinoma 80
Animal models of hepatocellular carcinoma prevention 80
Towards precision medicine: a preliminary collection of patient-derived organoids for the screening of personalised therapies in hepatocellular carcinoma 78
MiR-22 downregulation activates HIF-1A pathway and induces tumour progression, metabolic reprogramming and sorafenib resistance in hepatocellular carcinoma 78
MiR-494 induces metabolic reprogramming through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma 77
The tumour suppressor miR-22 induces metabolic reprogramming through GLUT1 targeting and represents a possible biomarker of Sorafenib response in Hepatocellular Carcinoma 74
CXCL3 is a target of miR-30e-3p and predicts tumor escape in sorafenib-treated HCC patients. 72
miR-30e-3p/CXCL3 axis predicts early tumor escape in sorafenib-treated HCC patients. 70
Pathophysiology roles and translational opportunities of miRNAs in hepatocellular carcinoma 70
Local hypothyroidism favours the progression of rat preneoplastic lesions to HCC 67
Anti-Tumor Activity of a miR-199-dependent Oncolytic Adenovirus 66
MiR-494 induces metabolic reprogramming through G6pc targeting and modulates sorafenib response in hepatocellular carcinoma 64
Circulating miR-106b-3p, miR-101-3p and miR-1246 as diagnostic biomarkers of hepatocellular carcinoma 64
MicroRNA and hepatocellular carcinoma: biology and prognostic significance 64
MiR-22 regulates HIF-1A pathway and tumor progression and represents a possible biomarker of sorafenib response in hepatocellular carcinoma 61
Metabolic reprogramming identifies the most aggressive lesions at early phases of hepatic cencerogenesis 60
MiR-30e-3p plays a dual role in hepatocellular carcinoma and predicts tumour escape to sorafenib Treatment 55
The metabolic gene HAO2 is downregulated in hepatocellular carcinoma and predicts metastasis and poor survival 53
Circulating miR-22 Early Predicts TACE Non-Response and Targets WEE1 in Hepatocellular Carcinoma 46
Totale 10.299
Salva come PNG Salva come JPEG
Categoria #
all - tutte 29.892
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 29.892
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022808 0 20 44 75 60 39 12 120 28 82 215 113
2022/2023936 90 95 56 103 52 78 23 55 164 27 72 121
2023/2024375 40 51 12 47 41 80 8 17 12 27 13 27
2024/20251.506 79 211 126 101 159 48 110 36 37 168 111 320
2025/20264.564 370 378 335 263 350 293 521 219 974 306 237 318
2026/2027340 247 93 0 0 0 0 0 0 0 0 0 0
Totale 10.299